Lisata Therapeutics amends merger agreement with Kuva Labs, setting $4.00 per share price plus CVRs

Lisata Therapeutics and Kuva Labs amended their merger agreement dated March 6, 2026, revising the offer price to $4.00 per share in cash plus one contingent value right (CVR) per share for future milestone payments. The amendment extends the offer commencement timeline and modifies key merger terms including the CVR agreement structure.